

**Kilrush Pharmacy Limited**  
**Abridged Financial Statements**  
**for the financial year ended 30 April 2025**

# Kilrush Pharmacy Limited

## CONTENTS

	<b>Page</b>
Directors' Responsibilities Statement	3
Independent Auditor's Special Report to the Directors	4 - 6
Appendix to the Independent Auditor's Report	7
Statement of Financial Position	8
Statement of Changes in Equity	9
Notes to the Financial Statements	10 - 15

# **Kilrush Pharmacy Limited**

## **DIRECTORS' RESPONSIBILITIES STATEMENT**

for the financial year ended 30 April 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### **Disclosure of Information to Auditor**

Each persons who are directors at the date of approval of this report confirms that:

- there is no relevant audit information (information needed by the company's auditor in connection with preparing the auditor's report) of which the company's auditor is unaware, and
- the directors have taken all the steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

### **Signed on behalf of the board**

**John Duffy**  
Director

**23 July 2025**

**Gerry Minogue**  
Director

**23 July 2025**

# **INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE DIRECTORS OF KILRUSH PHARMACY LIMITED**

## **pursuant to section 356(1) and 356(2) of the Companies Act 2014**

### **Opinion**

In our opinion the directors are entitled under section 352 of the Companies Act 2014 to annex to the annual return of the company the abridged financial statements and those abridged financial statements have been properly prepared pursuant to the provisions of section 353 of that Act (exemptions available to small companies).

### **Basis of opinion**

We have examined :

- (i) the abridged financial statements for the financial year ended 30 April 2025 on pages 8 to 15 which the directors of Kilrush Pharmacy Limited propose to annex to the annual return of the company; and
- (ii) the financial statements to be laid before the Annual General Meeting, which form the basis for those abridged financial statements.

The scope of our work for the purpose of this report was limited to confirming that the directors are entitled to annex abridged financial statements to the annual return and that those abridged financial statements have been properly prepared, pursuant to section 353 of the Companies Act 2014, from the financial statements to be laid before the Annual General Meeting.

### **Respective responsibilities of directors and auditors**

It is your responsibility to prepare abridged financial statements which comply with section 352 of the Companies Act 2014. It is our responsibility to form an independent opinion that the directors are entitled under section 352 of the Companies Act 2014 to annex abridged financial statements to the annual return of the company and that those abridged financial statements have been properly prepared pursuant to sections 352 and 353 of that Act and to report our opinion to you.

This report is made solely to the company's directors, as a body, in accordance with section 356(2) of the Companies Act 2014. Our work has been undertaken so that we might state to the directors those matters we are required to state to them in our report under section 356(2) of the Companies Act 2014 and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the directors for our work, for this report, or for the opinions we have formed.

### **Other Information required by the Companies Act 2014**

On 23 July 2025 we reported to the members on the company's financial statements for the financial year ended 30 April 2025 and our report was as follows:

#### **"Report on the audit of the financial statements**

### **Opinion**

We have audited the financial statements of Kilrush Pharmacy Limited ('the company') for the financial year ended 30 April 2025 which comprise the Income Statement, the Statement of Financial Position, the Statement of Changes in Equity and the related notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued in the United Kingdom by the Financial Reporting Council.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 30 April 2025 and of its profit for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

# **INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE DIRECTORS OF KILRUSH PHARMACY LIMITED**

## **pursuant to section 356(1) and 356(2) of the Companies Act 2014**

### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

### **Other Information**

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Opinions on other matters prescribed by the Companies Act 2014**

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

### **Matters on which we are required to report by exception**

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

### **Respective responsibilities**

#### **Responsibilities of directors for the financial statements**

As explained more fully in the Directors' Responsibilities Statement set out on page 3, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.

# **INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE DIRECTORS OF KILRUSH PHARMACY LIMITED**

## **pursuant to section 356(1) and 356(2) of the Companies Act 2014**

### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is contained in the appendix to this report, located at page 7, which is to be read as an integral part of our report.

### **The purpose of our audit work and to whom we owe our responsibilities**

Our report is made solely to the company's shareholders, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's shareholders those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's shareholders, as a body, for our audit work, for this report, or for the opinions we have formed."

**Caoimhín Broderick F.C.A.**  
**for and on behalf of**  
**MOORE IRELAND AUDIT PARTNERS LIMITED**  
Registered Auditors  
Galway Financial Services Centre  
Moneenageisha Road  
Galway

**23 July 2025**

We certify that the auditor's report on pages 4 - 6 made pursuant to section 356(1) of the Companies Act 2014 is a true copy of the original.

**Gerry Minogue**  
**Secretary**

**23 July 2025**

**John Duffy**  
**Director**

**23 July 2025**

# Kilrush Pharmacy Limited

## APPENDIX TO THE INDEPENDENT AUDITOR'S REPORT

### Further information regarding the scope of our responsibilities as auditor

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

**Kilrush Pharmacy Limited**  
**STATEMENT OF FINANCIAL POSITION**

as at 30 April 2025

	Notes	2025 €	2024 €
<b>Non-Current Assets</b>			
Property, plant and equipment	8	2,410,928	2,401,894
Financial assets	9	1,647,662	1,647,662
<b>Non-Current Assets</b>		<b>4,058,590</b>	<b>4,049,556</b>
<b>Current Assets</b>			
Inventories	10	167,402	160,675
Receivables	11	265,622	252,615
Cash and cash equivalents		3,276,001	2,990,637
		<b>3,709,025</b>	<b>3,403,927</b>
<b>Payables: amounts falling due within one year</b>	12	<b>(212,958)</b>	<b>(225,520)</b>
<b>Net Current Assets</b>		<b>3,496,067</b>	<b>3,178,407</b>
<b>Total Assets less Current Liabilities</b>		<b>7,554,657</b>	<b>7,227,963</b>
<b>Equity</b>			
Called up share capital presented as equity		200	200
Other reserves	13	2	2
Retained earnings		7,554,455	7,227,761
<b>Equity attributable to owners of the company</b>		<b>7,554,657</b>	<b>7,227,963</b>

We as Directors of Kilrush Pharmacy Limited, state that -

The company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that it is entitled to the benefit of that exemption as a small company and confirm that the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 23 July 2025 and signed on its behalf by:

**John Duffy**  
Director

**Gerry Minogue**  
Director

**Kilrush Pharmacy Limited**  
**STATEMENT OF CHANGES IN EQUITY**

as at 30 April 2025

	Called up share capital €	Retained earnings €	Capital redemption reserve €	Total €
<b>At 1 May 2023</b>	200	6,834,207	2	6,834,409
Profit for the financial year	-	508,554	-	508,554
Payment of dividends	-	(115,000)	-	(115,000)
<b>At 30 April 2024</b>	200	7,227,761	2	7,227,963
Profit for the financial year	-	526,694	-	526,694
Payment of dividends	-	(200,000)	-	(200,000)
<b>At 30 April 2025</b>	<b>200</b>	<b>7,554,455</b>	<b>2</b>	<b>7,554,657</b>

# Kilrush Pharmacy Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

### 1. General Information

Kilrush Pharmacy Limited is a company limited by shares incorporated in Ireland.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the year ended 30 April 2025 have been prepared on the going concern basis and in accordance with generally accepted accounting principles in Ireland and Irish statute comprising the Companies Act 2014 and in accordance with the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland (FRS 102) issued by the Financial Reporting Council.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

#### Cash flow statement

The company has availed of the exemption in FRS 102 from the requirement to prepare a Statement of Cash Flows because it is classified as a small company.

#### Revenue

Turnover represents the total sales value, excluding value added tax, of sales made during the year.

#### Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	0%
Fixtures, fittings and equipment	-	10% / 20% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Depreciation is not provided on land and buildings as these are maintained, as a matter of company policy, by a programme of repair and refurbishment such that the residual values of these properties are at least equal to their book values. Having regard to this, it is the opinion of the Directors that depreciation of any such property as required by standard accounting practice would not be material.

#### Investment properties

Investment property is property held either to earn rental income, or for capital appreciation (including future re-development) or for both, but not for sale in the ordinary course of business.

Investment property is initially measured at cost, which includes the purchase cost and any directly attributable expenditure. Investment property is subsequently valued at its fair value at each reporting date, by professional external valuers. The difference between the fair value of an investment property at the reporting date and its carrying value prior to the valuation is recognised in the Income Statement as a fair value gain or loss. Any gain or loss on disposal of an investment property (calculated as the difference between the net proceeds from disposal and the carrying amount of the item) is recognised in the Income Statement.

#### Financial assets

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Income Statement in the year in which it is receivable.

# Kilrush Pharmacy Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

### Inventories

Stocks are valued at the lower of cost and net realisable value. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

### Trade and other receivables

Trade and other receivables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

### Trade and other payables

Trade and other payables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

### Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

### Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

### Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Income Statement annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Income Statement when received.

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

## 3. Significant accounting judgements and key sources of estimation uncertainty

(a) Establishing useful economic lives for depreciation purposes of tangible fixed assets.

The annual depreciation charge depends primarily on the estimated useful economic lives of each type of asset and estimates of residual values. The directors regularly review these asset useful economic lives and change them as necessary to reflect current thinking in remaining lives in light of perspective economic utilisation and physical condition of the assets concerned. Changes in asset useful lives can have an impact on depreciation and amortisation charges for the period. Details of the useful economic lives is included in the accounting policies.

<b>4. Operating profit</b>	<b>2025</b>	<b>2024</b>
	€	€
<b>Operating profit is stated after charging/(crediting):</b>		
Depreciation of property, plant and equipment	<b>5,729</b>	2,039
Government grants received	<b>(6,886)</b>	-
	<u><u>          </u></u>	<u><u>          </u></u>

## Kilrush Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

<b>5. Income from investments</b>	<b>2025</b>	2024
	€	€
Profit on disposal of investments	-	313
	<u>          </u>	<u>          </u>

## 6. Employees

The average monthly number of employees, including directors, during the financial year was 10, (2024 - 10).

	<b>2025</b>	2024
	<b>Number</b>	Number
Full Time	5	5
Part Time	5	5
	<u>          </u>	<u>          </u>
	<b>10</b>	10
	<u>          </u>	<u>          </u>

## 7. Tax on profit

	<b>2025</b>	2024
	€	€
<b>(a) Analysis of charge in the financial year</b>		

### Current tax:

Corporation tax at 12.50% (2024 - 12.50%)	<b>93,640</b>	90,987
Over provision in prior year	-	(1,567)
	<u>          </u>	<u>          </u>
Total current tax	<b>93,640</b>	89,420
	<u>          </u>	<u>          </u>

### (b) Factors affecting tax charge for the financial year

The tax assessed for the financial year differs from the standard rate of corporation tax in Republic of Ireland 12.50% (2024 - 12.50%). The differences are explained below:

	<b>2025</b>	2024
	€	€
Profit taxable at 12.50%	<b>620,334</b>	597,974
	<u>          </u>	<u>          </u>
Profit before tax		
multiplied by the standard rate of corporation tax		
in Republic of Ireland at 12.50% (2024 - 12.50%)	<b>77,542</b>	74,747
<b>Effects of:</b>		
Capital allowances for period in excess of depreciation	<b>(334)</b>	(582)
Non taxable adjustments	<b>(467)</b>	(626)
Tax at higher rates	<b>19,595</b>	18,562
Foreign tax credits	<b>(2,696)</b>	(1,114)
Adjustment to tax charge in respect of previous periods	-	(1,567)
	<u>          </u>	<u>          </u>
Total tax charge for the financial year (Note 7 (a))	<b>93,640</b>	89,420
	<u>          </u>	<u>          </u>

## Kilrush Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

### 8. Property, plant and equipment

	Land and buildings freehold €	Investment properties €	Fixtures, fittings and equipment €	Total €
<b>Cost</b>				
At 1 May 2024	121,437	2,276,312	149,645	2,547,394
Additions	-	-	14,763	14,763
At 30 April 2025	<u>121,437</u>	<u>2,276,312</u>	<u>164,408</u>	<u>2,562,157</u>
<b>Depreciation</b>				
At 1 May 2024	-	-	145,500	145,500
Charge for the financial year	-	-	5,729	5,729
At 30 April 2025	<u>-</u>	<u>-</u>	<u>151,229</u>	<u>151,229</u>
<b>Carrying amount</b>				
At 30 April 2025	<u><b>121,437</b></u>	<u><b>2,276,312</b></u>	<u><b>13,179</b></u>	<u><b>2,410,928</b></u>
At 30 April 2024	<u>121,437</u>	<u>2,276,312</u>	<u>4,145</u>	<u>2,401,894</u>

As required by the applicable financial reporting standard, FRS 102, the company directors have considered the carrying value of the company investment properties for evidence of impairment. The Directors are satisfied that there is no evidence of impairment at 30 April 2025. This will be kept under review by the company directors.

At the balance sheet date, the company directors are satisfied that the investment properties owned by the company are worth at least their original cost value.

### 9. Financial fixed assets

	Listed investments €	Other unlisted investments €	Total €
<b>Investments</b>			
<b>Cost</b>			
At 30 April 2025	<u>647,662</u>	<u>1,000,000</u>	<u>1,647,662</u>
<b>Carrying amount</b>			
At 30 April 2025	<u><b>647,662</b></u>	<u><b>1,000,000</b></u>	<u><b>1,647,662</b></u>
At 30 April 2024	<u>647,662</u>	<u>1,000,000</u>	<u>1,647,662</u>

### 10. Inventories

	2025 €	2024 €
Goods for resale	<u><b>167,402</b></u>	<u>160,675</u>

There are no material differences between the replacement cost of stock and the balance sheet amounts.

### 11. Receivables

	2025 €	2024 €
Trade receivables	<b>133,826</b>	129,678
Amounts owed by connected parties (Note 15)	<b>2,146</b>	2,146
Taxation	<b>108,996</b>	101,782
Prepayments	<b>20,654</b>	19,009
	<u><b>265,622</b></u>	<u>252,615</u>

## Kilrush Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

12. Payables	2025	2024
Amounts falling due within one year	€	€
Trade payables	39,009	60,324
Amounts owed to group undertakings	14,412	7,864
Taxation	94,173	89,514
Directors' current accounts (Note 14)	12,248	13,584
Other creditors	15,921	15,963
Accruals	37,195	38,271
	<u>212,958</u>	<u>225,520</u>

13. Income Statement	Income statement	Capital redemption reserve	Total
	€	€	€
At 1 May 2024	7,227,761	2	7,227,763
Profit for the financial year	526,694	-	526,694
Payment of dividends	(200,000)	-	(200,000)
At 30 April 2025	<u>7,554,455</u>	<u>2</u>	<u>7,554,457</u>

14. Directors' remuneration and transactions	2025	2024
	€	€
Remuneration	155,900	155,900
Pension contributions	13,307	11,897
	<u>169,207</u>	<u>167,797</u>

The following amounts are repayable to the directors:

	2025	2024
	€	€
John Duffy	7,681	7,681
Gerry Minogue	4,567	5,903
	<u>12,248</u>	<u>13,584</u>

### 15. Related party transactions

As permitted by the Companies Act 2014 the company had transactions with other connected parties. The following amounts are receivable at the financial year end:

	Balance 2025	Movement in year	Balance 2024	Maximum in year
	€	€	€	€
McLoughlin's of Ennis Limited	<u>2,146</u>	-	2,146	<u>21,220</u>

McLoughlin's of Ennis Limited and Kilrush Pharmacy Limited are both controlled by common Directors, Mr. John Duffy and Mr. Gerry Minogue. The amount owed from McLoughlin's of Ennis Limited at 1 May 2024 was €2,146. There was no expenses incurred or payments made by McLoughlin's of Ennis Limited during the year and the amount due from McLoughlin's of Ennis Limited at 30 April 2025 was €2,146.

In the opinion of the directors these amounts arise in the ordinary course of business and the terms of the amounts due are in accordance with the terms ordinarily offered by the company.

**Kilrush Pharmacy Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 30 April 2025

Transactions and balances with group company:

**Duffmin Limited**

Kilrush Pharmacy Limited and Duffmin are both controlled by common Directors, Mr. Gerry Minogue and Mr. John Duffy. Kilrush Pharmacy Limited owns 100% of the 'B' Ordinary Shares in Duffmin Limited.

During the year ended 30 April 2025 Duffmin Limited paid trade expenses totalling €6,548 on behalf of Kilrush Pharmacy Limited. At the balance sheet date, Kilrush Pharmacy owed €14,412 to Duffmin Limited (2024: €7,864)

The directors are satisfied that all transactions between related parties are at market rates and are on an arms length basis.

**16. Controlling interest**

The ultimate controlling party is John Duffy and Gerry Minogue

**17. Events After the End of the Reporting Period**

There have been no significant events affecting the company since the financial year-end.

**18. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on 23 July 2025.